Adicet Bio Q3 net loss $26.9M; positive ADI-001 Phase 1 data in LN/SLE; cash runway extended to H2 2027

Adicet Bio, Inc.

2025-Q3 EPS reported -$0.94

Positive Phase 1 ADI-001 data in 7 LN/SLE patients: SLEDAI-2K reductions, improved renal function, no Grade 2+ CRS or ICANS.
Plans FDA meeting Q1 2026 for potentially pivotal trial; initiation targeted Q2 2026.
Q3 2025 net loss $26.9M ($0.29 loss per share); R&D $22.9M, G&A $5.1M; cash $103.1M as of Sep 30.
Raised $74.8M net proceeds in October 2025 registered direct offering; cash runway into H2 2027.
ADI-212 regulatory filing for mCRPC on track Q1 2026; initial data expected H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.